Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Leukemia, Myeloid, Acute | 96 | 2024 | 3523 | 10.780 |
Why?
|
Isocitrate Dehydrogenase | 28 | 2023 | 871 | 4.850 |
Why?
|
fms-Like Tyrosine Kinase 3 | 15 | 2021 | 491 | 4.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 25 | 2023 | 11524 | 1.920 |
Why?
|
Antineoplastic Agents | 28 | 2024 | 13695 | 1.680 |
Why?
|
Glutarates | 5 | 2018 | 236 | 1.650 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 | 2022 | 1519 | 1.650 |
Why?
|
Cytarabine | 14 | 2023 | 692 | 1.610 |
Why?
|
Hematopoietic Stem Cell Transplantation | 20 | 2023 | 5442 | 1.510 |
Why?
|
Protein Kinase Inhibitors | 15 | 2017 | 5535 | 1.430 |
Why?
|
Myelodysplastic Syndromes | 13 | 2024 | 1352 | 1.370 |
Why?
|
Azacitidine | 7 | 2023 | 347 | 1.370 |
Why?
|
Mutation | 37 | 2023 | 29786 | 1.340 |
Why?
|
Triazines | 6 | 2021 | 315 | 1.330 |
Why?
|
Myeloproliferative Disorders | 5 | 2024 | 606 | 1.310 |
Why?
|
Enzyme Inhibitors | 11 | 2021 | 3798 | 1.270 |
Why?
|
Leukemia, Myelomonocytic, Chronic | 3 | 2024 | 97 | 1.170 |
Why?
|
Aminopyridines | 6 | 2021 | 542 | 1.170 |
Why?
|
Leukocytosis | 4 | 2020 | 247 | 1.120 |
Why?
|
Azepines | 2 | 2019 | 336 | 1.100 |
Why?
|
Leukemia, Myeloid | 4 | 2019 | 707 | 1.060 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2020 | 689 | 1.010 |
Why?
|
Leukemia, Promyelocytic, Acute | 2 | 2018 | 236 | 0.990 |
Why?
|
Immunoconjugates | 3 | 2020 | 901 | 0.960 |
Why?
|
Phenylurea Compounds | 7 | 2020 | 528 | 0.920 |
Why?
|
Bone Marrow | 8 | 2017 | 2948 | 0.880 |
Why?
|
SEER Program | 6 | 2022 | 1508 | 0.840 |
Why?
|
Chromosomes, Human, Pair 17 | 2 | 2014 | 437 | 0.840 |
Why?
|
Eosinophilia | 4 | 2020 | 541 | 0.800 |
Why?
|
Glycine | 6 | 2022 | 671 | 0.760 |
Why?
|
Remission Induction | 16 | 2022 | 2386 | 0.740 |
Why?
|
Myelopoiesis | 1 | 2021 | 133 | 0.730 |
Why?
|
Long QT Syndrome | 1 | 2023 | 453 | 0.650 |
Why?
|
Hematologic Neoplasms | 6 | 2023 | 1832 | 0.650 |
Why?
|
Philadelphia Chromosome | 3 | 2021 | 112 | 0.650 |
Why?
|
Niacinamide | 3 | 2016 | 417 | 0.640 |
Why?
|
Hypereosinophilic Syndrome | 2 | 2021 | 93 | 0.640 |
Why?
|
Pyrimidines | 4 | 2020 | 2942 | 0.640 |
Why?
|
Pyridines | 7 | 2023 | 2825 | 0.620 |
Why?
|
Leukemia, Neutrophilic, Chronic | 1 | 2016 | 12 | 0.590 |
Why?
|
Humans | 151 | 2024 | 744343 | 0.590 |
Why?
|
Receptors, Colony-Stimulating Factor | 1 | 2016 | 49 | 0.580 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 1 | 2018 | 272 | 0.570 |
Why?
|
Communicable Diseases | 2 | 2017 | 880 | 0.570 |
Why?
|
Aged | 67 | 2023 | 163280 | 0.520 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 2 | 2013 | 34 | 0.520 |
Why?
|
Anilides | 1 | 2017 | 408 | 0.490 |
Why?
|
Blood Cells | 2 | 2016 | 309 | 0.490 |
Why?
|
Core Binding Factors | 1 | 2014 | 31 | 0.490 |
Why?
|
Hedgehog Proteins | 1 | 2019 | 783 | 0.490 |
Why?
|
Sarcoma, Myeloid | 1 | 2014 | 59 | 0.480 |
Why?
|
Oncogene Proteins, Fusion | 5 | 2022 | 1581 | 0.480 |
Why?
|
Benzimidazoles | 3 | 2020 | 850 | 0.470 |
Why?
|
Aged, 80 and over | 36 | 2021 | 57776 | 0.460 |
Why?
|
Translocation, Genetic | 3 | 2014 | 1420 | 0.460 |
Why?
|
Edema | 2 | 2021 | 789 | 0.450 |
Why?
|
Idarubicin | 3 | 2019 | 62 | 0.440 |
Why?
|
Aminoglycosides | 1 | 2013 | 162 | 0.440 |
Why?
|
Middle Aged | 63 | 2023 | 213383 | 0.440 |
Why?
|
Molecular Targeted Therapy | 3 | 2021 | 2727 | 0.430 |
Why?
|
Immunotherapy | 5 | 2022 | 4445 | 0.420 |
Why?
|
Tandem Repeat Sequences | 4 | 2016 | 185 | 0.420 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2013 | 417 | 0.410 |
Why?
|
Leukemia, Erythroblastic, Acute | 1 | 2012 | 189 | 0.410 |
Why?
|
Graft vs Host Disease | 4 | 2022 | 2957 | 0.410 |
Why?
|
Chromosomes, Human, Pair 15 | 1 | 2013 | 373 | 0.410 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2012 | 166 | 0.400 |
Why?
|
Ear, External | 1 | 2012 | 161 | 0.400 |
Why?
|
Epigenesis, Genetic | 4 | 2021 | 3647 | 0.400 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2014 | 415 | 0.390 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2019 | 5172 | 0.390 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2013 | 222 | 0.390 |
Why?
|
Carbazoles | 2 | 2011 | 226 | 0.380 |
Why?
|
Survival Rate | 14 | 2021 | 12788 | 0.380 |
Why?
|
Male | 70 | 2023 | 350118 | 0.380 |
Why?
|
Recurrence | 9 | 2023 | 8340 | 0.380 |
Why?
|
Female | 71 | 2023 | 380194 | 0.380 |
Why?
|
Neutrophil Infiltration | 1 | 2013 | 390 | 0.380 |
Why?
|
Ear Diseases | 1 | 2012 | 170 | 0.370 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 407 | 0.370 |
Why?
|
Antimetabolites, Antineoplastic | 5 | 2021 | 640 | 0.370 |
Why?
|
Maximum Tolerated Dose | 5 | 2019 | 892 | 0.360 |
Why?
|
Adult | 49 | 2023 | 214055 | 0.360 |
Why?
|
Immunologic Factors | 2 | 2018 | 1580 | 0.350 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1401 | 0.350 |
Why?
|
Mastocytosis | 1 | 2011 | 160 | 0.340 |
Why?
|
Rectum | 1 | 2014 | 904 | 0.330 |
Why?
|
Disease-Free Survival | 9 | 2021 | 6895 | 0.330 |
Why?
|
Salvage Therapy | 4 | 2019 | 1275 | 0.330 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2023 | 9239 | 0.330 |
Why?
|
Piperidines | 2 | 2013 | 1602 | 0.310 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1061 | 0.300 |
Why?
|
Insurance Coverage | 2 | 2023 | 1901 | 0.290 |
Why?
|
Eosinophils | 1 | 2011 | 955 | 0.290 |
Why?
|
Skin Neoplasms | 4 | 2023 | 5686 | 0.280 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2010 | 671 | 0.280 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 895 | 0.270 |
Why?
|
Apoptosis | 4 | 2020 | 9727 | 0.270 |
Why?
|
Prognosis | 21 | 2021 | 29063 | 0.270 |
Why?
|
Vincristine | 2 | 2022 | 1039 | 0.260 |
Why?
|
Transplantation, Homologous | 8 | 2019 | 4776 | 0.260 |
Why?
|
Pyrroles | 3 | 2018 | 1146 | 0.260 |
Why?
|
Splenomegaly | 2 | 2016 | 190 | 0.250 |
Why?
|
Soft Tissue Neoplasms | 1 | 2014 | 1363 | 0.250 |
Why?
|
Insurance, Health | 1 | 2017 | 2494 | 0.250 |
Why?
|
Survival Analysis | 10 | 2020 | 10252 | 0.240 |
Why?
|
Skin Diseases | 1 | 2013 | 1065 | 0.240 |
Why?
|
Mast Cells | 1 | 2011 | 1544 | 0.240 |
Why?
|
Leukemia | 3 | 2023 | 1511 | 0.240 |
Why?
|
Quality of Life | 9 | 2023 | 12804 | 0.240 |
Why?
|
Acute Disease | 7 | 2023 | 7149 | 0.240 |
Why?
|
Young Adult | 22 | 2021 | 56430 | 0.230 |
Why?
|
Neoplasms | 5 | 2023 | 21683 | 0.230 |
Why?
|
Retrospective Studies | 25 | 2021 | 77449 | 0.220 |
Why?
|
Mitoxantrone | 2 | 2019 | 152 | 0.210 |
Why?
|
Treatment Outcome | 18 | 2023 | 63114 | 0.210 |
Why?
|
Proportional Hazards Models | 6 | 2022 | 12354 | 0.210 |
Why?
|
Benzodiazepines | 2 | 2018 | 1101 | 0.210 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 7913 | 0.210 |
Why?
|
Incidence | 5 | 2023 | 20947 | 0.200 |
Why?
|
Thrombocytopenia | 2 | 2023 | 1179 | 0.200 |
Why?
|
Etoposide | 2 | 2019 | 641 | 0.190 |
Why?
|
Cell Cycle | 1 | 2009 | 2967 | 0.190 |
Why?
|
Primary Myelofibrosis | 1 | 2023 | 215 | 0.190 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2012 | 1596 | 0.190 |
Why?
|
Glioma | 1 | 2016 | 3401 | 0.190 |
Why?
|
Drug Evaluation | 2 | 2020 | 647 | 0.190 |
Why?
|
Fatal Outcome | 2 | 2018 | 1850 | 0.190 |
Why?
|
Boron Compounds | 1 | 2022 | 178 | 0.190 |
Why?
|
Bone Neoplasms | 1 | 2013 | 2529 | 0.190 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.180 |
Why?
|
Benzothiazoles | 2 | 2011 | 248 | 0.180 |
Why?
|
Blast Crisis | 1 | 2020 | 103 | 0.180 |
Why?
|
Sulfonamides | 4 | 2022 | 1938 | 0.170 |
Why?
|
Age Factors | 7 | 2021 | 18370 | 0.170 |
Why?
|
Follow-Up Studies | 10 | 2019 | 39050 | 0.170 |
Why?
|
Genes, sry | 1 | 2018 | 5 | 0.170 |
Why?
|
Furans | 2 | 2011 | 194 | 0.170 |
Why?
|
Medicare Part C | 1 | 2023 | 296 | 0.170 |
Why?
|
Neoplasm, Residual | 3 | 2018 | 973 | 0.160 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2014 | 4034 | 0.160 |
Why?
|
Medical Oncology | 5 | 2023 | 2265 | 0.160 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2022 | 841 | 0.160 |
Why?
|
Tretinoin | 1 | 2021 | 517 | 0.160 |
Why?
|
Cytogenetic Analysis | 2 | 2019 | 295 | 0.160 |
Why?
|
Fatigue | 2 | 2016 | 1531 | 0.160 |
Why?
|
Cyclopentanes | 1 | 2018 | 91 | 0.160 |
Why?
|
Pleural Effusion | 1 | 2021 | 338 | 0.150 |
Why?
|
Demography | 1 | 2022 | 1656 | 0.150 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4933 | 0.150 |
Why?
|
Antigens, CD19 | 1 | 2020 | 380 | 0.150 |
Why?
|
Respiration Disorders | 1 | 2021 | 371 | 0.150 |
Why?
|
Isoenzymes | 2 | 2020 | 1726 | 0.150 |
Why?
|
Databases, Factual | 4 | 2018 | 7729 | 0.150 |
Why?
|
Histocompatibility | 1 | 2018 | 330 | 0.150 |
Why?
|
Adolescent | 14 | 2021 | 85781 | 0.150 |
Why?
|
Terminal Care | 2 | 2021 | 1694 | 0.140 |
Why?
|
Immune Evasion | 1 | 2020 | 360 | 0.140 |
Why?
|
Combined Modality Therapy | 3 | 2018 | 8642 | 0.140 |
Why?
|
Mutant Proteins | 1 | 2018 | 500 | 0.140 |
Why?
|
Adenocarcinoma | 1 | 2014 | 6364 | 0.140 |
Why?
|
Asparaginase | 1 | 2017 | 236 | 0.140 |
Why?
|
Gene Frequency | 3 | 2018 | 3588 | 0.140 |
Why?
|
Sweating | 1 | 2016 | 123 | 0.140 |
Why?
|
Lung | 1 | 2014 | 9856 | 0.130 |
Why?
|
Pyrazines | 2 | 2019 | 1230 | 0.130 |
Why?
|
Multivariate Analysis | 5 | 2020 | 12245 | 0.130 |
Why?
|
DNA Methylation | 3 | 2020 | 4286 | 0.130 |
Why?
|
Cell Differentiation | 4 | 2021 | 11483 | 0.130 |
Why?
|
Transplantation Chimera | 1 | 2018 | 612 | 0.130 |
Why?
|
Antifungal Agents | 1 | 2020 | 730 | 0.130 |
Why?
|
Marital Status | 1 | 2017 | 437 | 0.130 |
Why?
|
Body Mass Index | 1 | 2013 | 12720 | 0.130 |
Why?
|
Anemia, Macrocytic | 1 | 2015 | 55 | 0.130 |
Why?
|
Dendritic Cells | 3 | 2023 | 2725 | 0.130 |
Why?
|
Leukemia, Myeloid, Accelerated Phase | 1 | 2014 | 7 | 0.130 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2023 | 2948 | 0.130 |
Why?
|
Biochemical Phenomena | 1 | 2015 | 59 | 0.130 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 12959 | 0.130 |
Why?
|
Hypotension | 1 | 2021 | 884 | 0.120 |
Why?
|
Aniline Compounds | 1 | 2019 | 986 | 0.120 |
Why?
|
Leukemia, Myeloid, Chronic-Phase | 1 | 2014 | 38 | 0.120 |
Why?
|
Cell Division | 1 | 2022 | 4568 | 0.120 |
Why?
|
Leukocyte Transfusion | 1 | 2014 | 60 | 0.120 |
Why?
|
Hospice Care | 1 | 2021 | 672 | 0.120 |
Why?
|
Glutamine | 1 | 2017 | 578 | 0.120 |
Why?
|
DNA Mutational Analysis | 4 | 2022 | 4186 | 0.120 |
Why?
|
Antibodies, Bispecific | 1 | 2016 | 164 | 0.120 |
Why?
|
Transplantation Conditioning | 2 | 2018 | 1598 | 0.120 |
Why?
|
United States | 9 | 2023 | 69872 | 0.120 |
Why?
|
Glutaminase | 1 | 2013 | 35 | 0.120 |
Why?
|
Thiadiazoles | 1 | 2013 | 55 | 0.120 |
Why?
|
Hematinics | 1 | 2017 | 281 | 0.120 |
Why?
|
Chromosomes, Human, Pair 21 | 1 | 2014 | 230 | 0.120 |
Why?
|
Elafin | 1 | 2013 | 33 | 0.120 |
Why?
|
Fever | 1 | 2021 | 1616 | 0.110 |
Why?
|
Stress Disorders, Post-Traumatic | 2 | 2021 | 4266 | 0.110 |
Why?
|
Anthracyclines | 2 | 2019 | 288 | 0.110 |
Why?
|
Granulocyte Precursor Cells | 1 | 2012 | 43 | 0.110 |
Why?
|
Sulfides | 1 | 2013 | 165 | 0.110 |
Why?
|
CCAAT-Enhancer-Binding Proteins | 1 | 2014 | 286 | 0.110 |
Why?
|
Cladribine | 1 | 2012 | 34 | 0.110 |
Why?
|
Practice Guidelines as Topic | 1 | 2010 | 7279 | 0.110 |
Why?
|
Retreatment | 1 | 2014 | 610 | 0.110 |
Why?
|
Nuclear Proteins | 3 | 2018 | 5853 | 0.110 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2016 | 627 | 0.110 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2014 | 460 | 0.100 |
Why?
|
Gene Expression Regulation, Leukemic | 2 | 2013 | 651 | 0.100 |
Why?
|
Animals | 10 | 2023 | 168757 | 0.100 |
Why?
|
Hematopoietic Stem Cells | 2 | 2016 | 3386 | 0.100 |
Why?
|
Antibiotic Prophylaxis | 1 | 2017 | 639 | 0.100 |
Why?
|
Human T-lymphotropic virus 1 | 1 | 2012 | 140 | 0.100 |
Why?
|
Syndrome | 1 | 2018 | 3251 | 0.100 |
Why?
|
Boston | 3 | 2021 | 9313 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2021 | 1855 | 0.100 |
Why?
|
Venous Thrombosis | 1 | 2021 | 1239 | 0.100 |
Why?
|
Dioxygenases | 1 | 2014 | 316 | 0.100 |
Why?
|
Mutagenesis, Insertional | 1 | 2014 | 655 | 0.100 |
Why?
|
Immunotherapy, Adoptive | 1 | 2020 | 1270 | 0.100 |
Why?
|
Biopsy | 2 | 2014 | 6756 | 0.100 |
Why?
|
Medically Uninsured | 1 | 2017 | 853 | 0.100 |
Why?
|
Kaplan-Meier Estimate | 4 | 2017 | 6538 | 0.100 |
Why?
|
Colony-Forming Units Assay | 1 | 2011 | 356 | 0.100 |
Why?
|
Affect | 1 | 2019 | 1476 | 0.100 |
Why?
|
Adaptation, Psychological | 4 | 2022 | 2576 | 0.100 |
Why?
|
Cough | 1 | 2014 | 555 | 0.100 |
Why?
|
Core Binding Factor Alpha 2 Subunit | 1 | 2013 | 345 | 0.100 |
Why?
|
Vidarabine | 1 | 2012 | 345 | 0.090 |
Why?
|
Cyclooxygenase 2 | 1 | 2013 | 611 | 0.090 |
Why?
|
Staurosporine | 1 | 2011 | 251 | 0.090 |
Why?
|
Anxiety | 5 | 2023 | 4297 | 0.090 |
Why?
|
Hospitalization | 3 | 2021 | 10262 | 0.090 |
Why?
|
Leukapheresis | 2 | 2020 | 131 | 0.090 |
Why?
|
Risk Factors | 10 | 2021 | 72290 | 0.090 |
Why?
|
Needs Assessment | 1 | 2016 | 1147 | 0.090 |
Why?
|
Hypercalcemia | 1 | 2012 | 409 | 0.090 |
Why?
|
Stomach | 1 | 2014 | 697 | 0.090 |
Why?
|
Educational Status | 1 | 2017 | 2540 | 0.080 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2008 | 5221 | 0.080 |
Why?
|
Cell Survival | 3 | 2020 | 5882 | 0.080 |
Why?
|
Radiography, Abdominal | 1 | 2012 | 537 | 0.080 |
Why?
|
Immunoprecipitation | 1 | 2011 | 905 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 17446 | 0.080 |
Why?
|
Critical Care | 1 | 2021 | 2647 | 0.080 |
Why?
|
Patient Admission | 1 | 2016 | 1380 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3703 | 0.080 |
Why?
|
Skull | 1 | 2013 | 813 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2021 | 1972 | 0.080 |
Why?
|
Odds Ratio | 3 | 2020 | 9849 | 0.080 |
Why?
|
Treatment Failure | 1 | 2014 | 2618 | 0.080 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2013 | 789 | 0.080 |
Why?
|
Clone Cells | 1 | 2011 | 1692 | 0.080 |
Why?
|
Income | 1 | 2017 | 1913 | 0.080 |
Why?
|
Social Class | 1 | 2017 | 1999 | 0.080 |
Why?
|
Massachusetts | 1 | 2021 | 8663 | 0.080 |
Why?
|
Consciousness Disorders | 1 | 2012 | 418 | 0.080 |
Why?
|
Cause of Death | 2 | 2021 | 3584 | 0.080 |
Why?
|
beta Catenin | 1 | 2013 | 1059 | 0.080 |
Why?
|
Immunohistochemistry | 2 | 2022 | 11366 | 0.080 |
Why?
|
Recombinant Fusion Proteins | 1 | 2016 | 3772 | 0.070 |
Why?
|
Prospective Studies | 5 | 2021 | 53288 | 0.070 |
Why?
|
Prednisone | 1 | 2012 | 1574 | 0.070 |
Why?
|
Chest Pain | 1 | 2014 | 1114 | 0.070 |
Why?
|
Anemia | 1 | 2017 | 1506 | 0.070 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2016 | 2540 | 0.070 |
Why?
|
Diarrhea | 1 | 2014 | 1348 | 0.070 |
Why?
|
Head | 1 | 2012 | 880 | 0.070 |
Why?
|
Drug Therapy, Combination | 2 | 2020 | 6489 | 0.070 |
Why?
|
Dyspnea | 1 | 2014 | 1303 | 0.070 |
Why?
|
Breast Neoplasms | 1 | 2014 | 20822 | 0.070 |
Why?
|
Chromosome Aberrations | 1 | 2013 | 1813 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2017 | 2073 | 0.070 |
Why?
|
Flavonoids | 1 | 2009 | 443 | 0.070 |
Why?
|
Cyclophosphamide | 1 | 2012 | 2242 | 0.070 |
Why?
|
Patient Acceptance of Health Care | 2 | 2021 | 3022 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2019 | 3679 | 0.070 |
Why?
|
Abdominal Pain | 1 | 2012 | 1063 | 0.070 |
Why?
|
Genotype | 2 | 2021 | 12951 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2022 | 9959 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2019 | 5317 | 0.070 |
Why?
|
Poverty | 1 | 2017 | 2660 | 0.060 |
Why?
|
Random Allocation | 2 | 2021 | 2429 | 0.060 |
Why?
|
Neoplastic Stem Cells | 1 | 2013 | 1376 | 0.060 |
Why?
|
Neurodegenerative Diseases | 1 | 2014 | 1061 | 0.060 |
Why?
|
Ventricular Function, Left | 1 | 2017 | 3670 | 0.060 |
Why?
|
Echocardiography | 1 | 2017 | 5102 | 0.060 |
Why?
|
Population Surveillance | 1 | 2015 | 2616 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9274 | 0.060 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2649 | 0.060 |
Why?
|
Stroke Volume | 1 | 2017 | 5007 | 0.060 |
Why?
|
Insurance, Medigap | 1 | 2023 | 19 | 0.060 |
Why?
|
Neutrophils | 1 | 2016 | 3719 | 0.060 |
Why?
|
Signal Transduction | 3 | 2013 | 23403 | 0.060 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 2109 | 0.060 |
Why?
|
Medicaid | 1 | 2017 | 2736 | 0.060 |
Why?
|
Tablets | 1 | 2024 | 145 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5179 | 0.060 |
Why?
|
Diamines | 1 | 2023 | 59 | 0.060 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6314 | 0.060 |
Why?
|
Radiography | 1 | 2014 | 7023 | 0.060 |
Why?
|
Lung Neoplasms | 1 | 2008 | 13102 | 0.060 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 1 | 2023 | 39 | 0.060 |
Why?
|
Leukocyte Count | 2 | 2020 | 1588 | 0.050 |
Why?
|
Indoles | 1 | 2011 | 1839 | 0.050 |
Why?
|
Disease Management | 3 | 2020 | 2459 | 0.050 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2011 | 2503 | 0.050 |
Why?
|
Blood Transfusion | 2 | 2020 | 1301 | 0.050 |
Why?
|
Cardiomyopathies | 1 | 2014 | 1912 | 0.050 |
Why?
|
Depression | 4 | 2023 | 7766 | 0.050 |
Why?
|
Colitis, Ulcerative | 1 | 2014 | 1912 | 0.050 |
Why?
|
Time Factors | 4 | 2021 | 40075 | 0.050 |
Why?
|
Glioblastoma | 1 | 2016 | 3481 | 0.050 |
Why?
|
Proto-Oncogene Proteins | 1 | 2014 | 4554 | 0.050 |
Why?
|
Administration, Oral | 2 | 2019 | 3913 | 0.050 |
Why?
|
Quinuclidines | 1 | 2020 | 24 | 0.050 |
Why?
|
Nuclear Pore Complex Proteins | 1 | 2022 | 165 | 0.050 |
Why?
|
Heart Diseases | 1 | 2014 | 2788 | 0.050 |
Why?
|
Ultrasonography | 1 | 2014 | 5985 | 0.050 |
Why?
|
Anthracenes | 1 | 2020 | 84 | 0.050 |
Why?
|
Genome, Human | 1 | 2014 | 4420 | 0.050 |
Why?
|
Palliative Care | 3 | 2021 | 3493 | 0.050 |
Why?
|
Cohort Studies | 5 | 2021 | 40561 | 0.050 |
Why?
|
U937 Cells | 1 | 2020 | 268 | 0.040 |
Why?
|
Phosphorylation | 1 | 2011 | 8436 | 0.040 |
Why?
|
Hyperbilirubinemia | 1 | 2020 | 77 | 0.040 |
Why?
|
Skin | 1 | 2013 | 4364 | 0.040 |
Why?
|
North America | 1 | 2023 | 1249 | 0.040 |
Why?
|
Disease Progression | 2 | 2013 | 13284 | 0.040 |
Why?
|
Logistic Models | 3 | 2020 | 13408 | 0.040 |
Why?
|
Standard of Care | 1 | 2023 | 564 | 0.040 |
Why?
|
Registries | 1 | 2014 | 8089 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
Prednisolone | 1 | 2018 | 334 | 0.040 |
Why?
|
Histocompatibility Testing | 1 | 2019 | 741 | 0.040 |
Why?
|
Cell Proliferation | 1 | 2013 | 10481 | 0.040 |
Why?
|
Off-Label Use | 1 | 2018 | 169 | 0.040 |
Why?
|
Death | 1 | 2021 | 678 | 0.040 |
Why?
|
Immunophenotyping | 1 | 2021 | 1880 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10943 | 0.040 |
Why?
|
Antilymphocyte Serum | 1 | 2018 | 492 | 0.040 |
Why?
|
Cytokines | 1 | 2011 | 7322 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2014 | 9648 | 0.030 |
Why?
|
Biphenyl Compounds | 1 | 2020 | 913 | 0.030 |
Why?
|
Molecular Structure | 1 | 2020 | 1899 | 0.030 |
Why?
|
Brain Neoplasms | 1 | 2016 | 8863 | 0.030 |
Why?
|
Diabetes Mellitus | 1 | 2013 | 5751 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1677 | 0.030 |
Why?
|
Cell Count | 1 | 2018 | 1856 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5319 | 0.030 |
Why?
|
Receptors, Immunologic | 1 | 2020 | 1423 | 0.030 |
Why?
|
HLA Antigens | 1 | 2019 | 1381 | 0.030 |
Why?
|
Cardiovascular Diseases | 1 | 2019 | 15165 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1782 | 0.030 |
Why?
|
Coronary Artery Disease | 1 | 2013 | 6487 | 0.030 |
Why?
|
Risk Assessment | 3 | 2019 | 23338 | 0.030 |
Why?
|
Neoplasm Staging | 1 | 2008 | 11031 | 0.030 |
Why?
|
Liver | 2 | 2019 | 7474 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2008 | 15540 | 0.030 |
Why?
|
Bone Marrow Examination | 1 | 2013 | 157 | 0.030 |
Why?
|
Benchmarking | 1 | 2019 | 1042 | 0.030 |
Why?
|
Switzerland | 1 | 2013 | 255 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2019 | 13989 | 0.030 |
Why?
|
Hemoglobins | 1 | 2018 | 1534 | 0.030 |
Why?
|
Perception | 1 | 2018 | 1198 | 0.030 |
Why?
|
K562 Cells | 1 | 2013 | 634 | 0.020 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2013 | 434 | 0.020 |
Why?
|
History, 21st Century | 1 | 2017 | 1534 | 0.020 |
Why?
|
Cyclooxygenase Inhibitors | 1 | 2013 | 371 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16689 | 0.020 |
Why?
|
Karyotyping | 1 | 2013 | 1243 | 0.020 |
Why?
|
Mortality | 1 | 2021 | 2864 | 0.020 |
Why?
|
Pilot Projects | 1 | 2023 | 8324 | 0.020 |
Why?
|
Pyrazoles | 1 | 2020 | 1972 | 0.020 |
Why?
|
Stem Cell Transplantation | 1 | 2018 | 1620 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2012 | 20129 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2020 | 3768 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2013 | 2085 | 0.020 |
Why?
|
Boronic Acids | 1 | 2013 | 965 | 0.020 |
Why?
|
Comorbidity | 2 | 2017 | 10388 | 0.020 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2013 | 1213 | 0.020 |
Why?
|
Thalidomide | 1 | 2013 | 890 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2014 | 1405 | 0.020 |
Why?
|
Protein Binding | 1 | 2020 | 9386 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2038 | 0.020 |
Why?
|
Mice, Nude | 1 | 2014 | 3689 | 0.020 |
Why?
|
Forecasting | 1 | 2016 | 2951 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3508 | 0.020 |
Why?
|
Genetic Variation | 1 | 2021 | 6544 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2017 | 3589 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2014 | 2455 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 25043 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2006 | 11727 | 0.020 |
Why?
|
Physician-Patient Relations | 1 | 2018 | 3229 | 0.020 |
Why?
|
Transplantation, Heterologous | 1 | 2013 | 2382 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2014 | 6386 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3887 | 0.020 |
Why?
|
Alleles | 1 | 2015 | 6933 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2020 | 8428 | 0.010 |
Why?
|
Monocytes | 1 | 2013 | 2596 | 0.010 |
Why?
|
Child | 2 | 2023 | 77709 | 0.010 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2015 | 3597 | 0.010 |
Why?
|
Gene Expression Regulation, Developmental | 1 | 2014 | 3617 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 5391 | 0.010 |
Why?
|
Genetic Testing | 1 | 2015 | 3444 | 0.010 |
Why?
|
Zebrafish | 1 | 2013 | 2994 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9734 | 0.010 |
Why?
|
Heart | 1 | 2014 | 4467 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2020 | 15519 | 0.010 |
Why?
|
Cell Line | 1 | 2014 | 15997 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9438 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15076 | 0.010 |
Why?
|
Mice | 2 | 2014 | 81183 | 0.010 |
Why?
|
Prevalence | 1 | 2006 | 15226 | 0.010 |
Why?
|